tiprankstipranks
Advertisement
Advertisement

ZVRA Stock Latest News

Zevra Therapeutics: Buy Rating Reiterated as MIPLYFFA Growth Conviction Strengthens and $26 Price Target Maintained
RatingsZevra Therapeutics: Buy Rating Reiterated as MIPLYFFA Growth Conviction Strengthens and $26 Price Target Maintained
4d ago
ZVRA
Zevra: Buy Rating Reaffirmed on Strong MIPLYFFA Momentum and U.S. NPC Opportunity; Price Target Maintained at $35
PremiumRatings
Zevra: Buy Rating Reaffirmed on Strong MIPLYFFA Momentum and U.S. NPC Opportunity; Price Target Maintained at $35
16d ago
ZVRA
Zevra Therapeutics price target lowered to $23 from $24 at Guggenheim
PremiumThe Fly
Zevra Therapeutics price target lowered to $23 from $24 at Guggenheim
17d ago
ZVRA
Kulkarni Reiterates Buy on Zevra, Citing Undervalued Niemann-Pick C Franchise, Celiprolol Upside, Strong Balance Sheet and Unchanged $20 Price Target
PremiumRatings
Kulkarni Reiterates Buy on Zevra, Citing Undervalued Niemann-Pick C Franchise, Celiprolol Upside, Strong Balance Sheet and Unchanged $20 Price Target
17d ago
ZVRA
Brandon Folkes Reiterates Buy on Zevra Therapeutics, Raising Price Target to $26 on Strong MIPLYFFA-Driven Outperformance
PremiumRatings
Brandon Folkes Reiterates Buy on Zevra Therapeutics, Raising Price Target to $26 on Strong MIPLYFFA-Driven Outperformance
18d ago
ZVRA
Analyst Reiterates Buy on Zevra as Strong Miplyffa Performance Offsets Arimoclomol Setback; $24 Price Target Maintained
PremiumRatingsAnalyst Reiterates Buy on Zevra as Strong Miplyffa Performance Offsets Arimoclomol Setback; $24 Price Target Maintained
18d ago
ZVRA
Zevra Therapeutics price target raised to $28 from $25 at Citizens
Premium
The Fly
Zevra Therapeutics price target raised to $28 from $25 at Citizens
18d ago
ZVRA
Zevra Pharmaceuticals: Strong Miplyffa Uptake, Arimoclomol EAP Momentum, and EU Re-examination Support Buy Rating
Premium
Ratings
Zevra Pharmaceuticals: Strong Miplyffa Uptake, Arimoclomol EAP Momentum, and EU Re-examination Support Buy Rating
18d ago
ZVRA
Zevra Therapeutics reports Q2 EPS 14c, consensus 16c
PremiumThe Fly
Zevra Therapeutics reports Q2 EPS 14c, consensus 16c
18d ago
ZVRA
Is ZVRA a Buy, Before Earnings?
PremiumPre-Earnings
Is ZVRA a Buy, Before Earnings?
21d ago
ZVRA
Spruce Biosciences appoints Quartel as Chief Medical Officer
PremiumThe Fly
Spruce Biosciences appoints Quartel as Chief Medical Officer
28d ago
SPRB
ZVRA
Zevra Therapeutics price target lowered to $24 from $29 at Guggenheim
PremiumThe Fly
Zevra Therapeutics price target lowered to $24 from $29 at Guggenheim
28d ago
ZVRA
Zevra Therapeutics price target lowered to $24 from $27 at BTIG
PremiumThe FlyZevra Therapeutics price target lowered to $24 from $27 at BTIG
28d ago
ZVRA
Zevra Therapeutics price target lowered to $20 from $29 at Canaccord
Premium
The Fly
Zevra Therapeutics price target lowered to $20 from $29 at Canaccord
28d ago
ZVRA
Midday Fly By: Intel reports Q2 beat, Anduril in talks for $100B valuation
Premium
The Fly
Midday Fly By: Intel reports Q2 beat, Anduril in talks for $100B valuation
1M ago
BP
EW
EU opinion ‘headwind, but not insurmountable’ for Zevra, says H.C. Wainwright
PremiumThe Fly
EU opinion ‘headwind, but not insurmountable’ for Zevra, says H.C. Wainwright
1M ago
ZVRA
Morning Movers: American Express dips after second quarter report
PremiumThe Fly
Morning Movers: American Express dips after second quarter report
1M ago
VZ
AXP
Zevra Therapeutics down 30% at $8.78 after negative CHMP opinion on arimoclomol
PremiumThe Fly
Zevra Therapeutics down 30% at $8.78 after negative CHMP opinion on arimoclomol
1M ago
ZVRA
Zevra Therapeutics announces negative CHMP opinion on arimoclomol MAA
PremiumThe Fly
Zevra Therapeutics announces negative CHMP opinion on arimoclomol MAA
1M ago
ZVRA
Zevra Therapeutics: New Infant MIPLYFFA Data Reinforce Core NPC Role; Buy Rating and $26 Price Target Reiterated
PremiumRatingsZevra Therapeutics: New Infant MIPLYFFA Data Reinforce Core NPC Role; Buy Rating and $26 Price Target Reiterated
2M ago
ZVRA
Zevra publishes Miplyffa data in Molecular Genetics, Metabolism Reports
Premium
The Fly
Zevra publishes Miplyffa data in Molecular Genetics, Metabolism Reports
2M ago
ZVRA
Zevra Therapeutics chief medical officer to step down
Premium
The Fly
Zevra Therapeutics chief medical officer to step down
2M ago
ZVRA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >